Search results for: 'meet fuels develop deceleration'

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

12 Aug 2021  |  North America  |  Frost Radar

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathog...

14 Jan 2019  |  North America  |  Market Research

Growth Opportunities in the Global qPCR and dPCR Market, Forecast to 2023

Novel Applications in Oncology and Applied Sciences, Growing Research and Diagnostic Use in Developing Regions, and Automated Modular Workflows to Drive Growth

Infographics

×

Key Issues Addressed

Overview: PCR continues to be the gold standard for nucleic acid amplification by combining accuracy and efficacy that users across areas such as research, pharma & biotech, diagnostics as well as applied sciences depend upon. Such widespread usage continues to drive the industry, even protecting it to some extent from overall economic/market fluct...

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...

08 Oct 2021  |  North America  |  Market Research

Global Tissue Diagnostics (TDx) Growth Opportunities

Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma

Infographics

×

This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...